Status:
UNKNOWN
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions:
Squamous Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in c...
Eligibility Criteria
Inclusion
- Squamous non-small cell lung cancer.
- A measurable lesion.
- The disease progression occurs \>12 months after the end of the last treatment. 4.18-75 years old ; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months.
- Adequate laboratory indicators. 6.No pregnant or breastfeeding women, and a negative pregnancy test. 7.Understood and signed an informed consent form.
Exclusion
- The tumor invades the large blood vessels.
- Central type squamous non-small cell lung cancer.
- EGFR/ALK gene mutation is positive.
- Has used EGFR inhibitors and ALK inhibitors.
- Has other malignant tumors within 5 years.
- Has a variety of factors affecting oral medications.
- Symptomatic brain metastasis.
- Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
- Spinal cord compression.
- Has received radiotherapy, chemotherapy, surgery less than 4 weeks before randomization.
- Severe allergies to therapeutic medications.
- Adverse events caused by previous treatment did not recover to grade 1.
- Has received major surgical treatment within 4 weeks before randomization.
- Arteriovenous thrombosis occurred within 6 months.
- Has drug abuse history that unable to abstain from or mental disorders.
- Has severe or uncontrolled disease.
- Participated in other clinical trials within 4 weeks.
- According to the investigators' judgement.
Key Trial Info
Start Date :
October 31 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
386 Patients enrolled
Trial Details
Trial ID
NCT04073537
Start Date
October 31 2019
End Date
June 30 2022
Last Update
August 29 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100083
2
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 50011